Santiago Osorio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5623625/publications.pdf

Version: 2024-02-01

1684188 1474206 8 97 5 9 citations g-index h-index papers 9 9 9 179 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. Blood Cancer Journal, 2018, 8, 91.	6.2	38
2	Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?. Annals of Hematology, 2018, 97, 2089-2098.	1.8	18
3	Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e985-e999.	0.4	13
4	PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase. PLoS ONE, 2017, 12, e0181366.	2.5	8
5	Potential drug interactions between targeted oral antineoplastic agents and concomitant medication in clinical practice. Expert Opinion on Drug Safety, 2020, 19, 1041-1048.	2.4	7
6	Severe liver toxicity in a chronic myeloid leukemia patient probably induced by a drug interaction between imatinib and sertraline. Journal of Oncology Pharmacy Practice, 2019, 25, 484-486.	0.9	5
7	A second administration of glucarpidase in a different cycle of high-dose methotrexate: Is it safe and effective in adults?. Journal of Oncology Pharmacy Practice, 2021, 27, 734-738.	0.9	4
8	Error Detection and Cost Savings With an Image-Based Workflow Management System Connected to a Computerized Prescription Order Entry Program for Antineoplastic Compounding. Journal of Patient Safety, 2019, Publish Ahead of Print, e1589-e1594.	1.7	3